Nabriva Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBRVF research report →
About the company
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration.
- CEO
- H. Michael Hogan
- IPO
- 2023
- Employees
- 39
- HQ
- Dublin, IE
Price Chart
- Market Cap
- $323
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
- Gross Margin
- 19.87%
- Op Margin
- -155.57%
- Net Margin
- -160.33%
- ROE
- -201.91%
- ROIC
- -617.04%
- Revenue
- $35.67M · 31.06%
- Net Income
- $-57,185,000 · -15.64%
- EPS
- $-21.32 · 25.25%
- Op Income
- $-55,490,000
- FCF YoY
- 38.03%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.68
- Avg Volume
- 59
Get TickerSpark's AI analysis on NBRVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NBRVF coverage
Recent articles, reports, and earnings notes.
No research on NBRVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBRVF report →Similar companies
Peers in the same neighborhood.